From the Editor

Brian C. Callaghan, MD, MS, and Kevin A. Kerber, MD, MS

Innovations in Care Delivery strives to highlight articles that feature advances in care delivery in our Editors' Blog, Editors' Top 5 Recommended Reading, and Latest Articles sections. Periodically, we also include interviews with leaders in the field of health services research.

Editors' Blog

The Innovations in Care Delivery blog, over the last several months, has discussed articles about the use of paraneoplastic testing panels that are commercially available,¹ starting antiepileptic drugs after a first unprovoked seizure,² and the role of monoclonal antibody testing against CGRP receptors.³ Our goal is to highlight health services research articles published in *Neurology*[®] or the subspecialty journals as well as to give opinions by experts in the field.

Editors' Top 5 Recommended Reading and Latest Articles

Check out our collection of *Neurology*[®] articles related to innovations in care delivery. A recent editorial by Drs. Jones and Patel⁴ discussed quality measurement in neurology. They acknowledged that quality measurement is yet another external pressure on neurologists, but development of these is incentivized by the Centers for Medicare & Medicaid Services. They also note that the American Academy of Neurology quality measure sets are mostly process measures and not outcome measures, and that process measures need to be evaluated for whether or not they actually result in desired outcomes.

Another new addition is the article by Hughes et al.⁵ about identifying patients who will not achieve seizure remission within 5 years on antiepileptic medicines. They found that 95% of no-remission patients were correctly identified, and that the majority of these patients are identified within the first 3 years after beginning treatment. Important predictors were presence of a neurologic insult (learning disabilities or neurologic deficit), age, treatment changes, and total seizures.

References

1. Ebright MJ, Li SH, Reynolds E, et al. Unintended consequences of Mayo paraneoplastic evaluations. *Neurology* Epub 2018 Oct 26.
2. Bao EL, Chao LY, Ni P, et al. Antiepileptic drug treatment after an unprovoked first seizure: a decision analysis. *Neurology* 2018;91:e1429–e1439.
3. VanderPluym J, Dodick DW, Lipton RB, et al. Fremanezumab for preventive treatment of migraine: functional status on headache-free days. *Neurology* 2018;91:e1152–e1165.
4. Jones LK Jr, Patel AD. The road to quality: paved with more than good intentions. *Neurology* 2018;91:817–819.
5. Hughes DM, Bonnett LJ, Czanner G, et al. Identification of patients who will not achieve seizure remission within 5 years on AEDs. *Neurology* Epub 2018 Nov 2.

Blog

Read the Innovations in Care Delivery blog for timely posts by the editors and invited guests on *Neurology* articles. NPub.org/icdblog

Neurology[®]

What's happening in Innovations in Care Delivery

Neurology 2019;92;75
DOI 10.1212/WNL.0000000000006753

This information is current as of January 7, 2019

Updated Information & Services

including high resolution figures, can be found at:
<http://n.neurology.org/content/92/2/75.full>

References

This article cites 3 articles, 3 of which you can access for free at:
<http://n.neurology.org/content/92/2/75.full#ref-list-1>

Permissions & Licensing

Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at:
http://www.neurology.org/about/about_the_journal#permissions

Reprints

Information about ordering reprints can be found online:
<http://n.neurology.org/subscribers/advertise>

Neurology® is the official journal of the American Academy of Neurology. Published continuously since 1951, it is now a weekly with 48 issues per year. Copyright © 2019 American Academy of Neurology. All rights reserved. Print ISSN: 0028-3878. Online ISSN: 1526-632X.